TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 196 filers reported holding TURNING POINT THERAPEUTICS I in Q4 2020. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $25,821,000 | +173.8% | 343,133 | -2.3% | 0.01% | +200.0% |
| Q1 2022 | $9,430,000 | -42.7% | 351,194 | +1.9% | 0.00% | -40.0% |
| Q4 2021 | $16,447,000 | -26.5% | 344,795 | +2.4% | 0.01% | -28.6% |
| Q3 2021 | $22,362,000 | -10.3% | 336,610 | +5.3% | 0.01% | -12.5% |
| Q2 2021 | $24,943,000 | -10.1% | 319,694 | +9.0% | 0.01% | -20.0% |
| Q1 2021 | $27,737,000 | -15.5% | 293,227 | +8.9% | 0.01% | -23.1% |
| Q4 2020 | $32,808,000 | +59.9% | 269,243 | +14.7% | 0.01% | +44.4% |
| Q3 2020 | $20,515,000 | +112.8% | 234,822 | +57.3% | 0.01% | +80.0% |
| Q2 2020 | $9,642,000 | +83.1% | 149,268 | +26.6% | 0.01% | +66.7% |
| Q1 2020 | $5,265,000 | -27.3% | 117,890 | +1.4% | 0.00% | -25.0% |
| Q4 2019 | $7,243,000 | +170.2% | 116,265 | +63.1% | 0.00% | +100.0% |
| Q3 2019 | $2,681,000 | +29.4% | 71,303 | +40.1% | 0.00% | +100.0% |
| Q2 2019 | $2,072,000 | – | 50,906 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
| Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
| Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
| Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
| Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
| Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
| Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
| DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |